Home>Topics>Finance>Technology>Biotechnology

Biotechnology

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. China approval may spur financial settlements for Syngenta -lawyers

    Headlines

    Thu, 18 Dec 2014

    Dec 18 (Reuters) - Chinese government approval for imports of a controversial type of Syngenta AG biotech corn increases the likelihood the seed maker will pay settlements to more than 100 U.S. farmers and exporters suing for damages

  2. UPDATE 2-China approves imports of Viptera corn, two types of soybeans- Vilsack

    Headlines

    Wed, 17 Dec 2014

    CHICAGO, Dec 17 (Reuters) - A top Chinese government official said the country has approved imports of genetically modified Agrisure Viptera corn and two varieties of biotech soybeans after years of review, U.S. Agriculture Secretary Tom Vilsack said on Wednesday.

  3. UPDATE 1-U.S, China making progress on biotech crop talks -USDA's Vilsack

    Headlines

    Wed, 17 Dec 2014

    (Updates with additional comments, background starting in fourth paragraph.)

  4. U.S, China making progress on biotech crop talks -USDA's Vilsack

    Headlines

    Wed, 17 Dec 2014

    CHICAGO, Dec 17 (Reuters) - The United States and China are making progress on talks over Beijing's acceptance of new biotechnology for crops, U.S. Agriculture Secretary Tom Vilsack said on Wednesday.

  5. Galapagos loses partner on inflammatory bowel drug

    Headlines

    Tue, 16 Dec 2014

    BRUSSELS, Dec 16 (Reuters) - Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a programme to develop a new drug to treat bowel disease.

  6. The Winners and Losers of U.S. Equity Funds in 2014

    Headlines

    Tue, 16 Dec 2014

    term prospects. Winner: Growth Funds That Like Health Care Primecap's growth funds are all fond of health care, including biotech , and they produced returns between 15% and 20%, all topping nearly all of their peers. ClearBridge Aggressive Growth SHRAX

  7. When Boring Becomes Exciting

    Headlines

    Mon, 15 Dec 2014

    generating free cash flows with sound balance sheets that are far removed from the headline exciting stocks in social media, biotech , internet shopping etc., currently being purchased by the investment masses ( who we believe are paying little attention

  8. Alnylam's R&D Day Highlights Broad and Compelling Pipeline, but Most Opportunities Are Still Early

    Commentary

    Mon, 15 Dec 2014

    several of its development programs. While Alnylam has one of the most plentiful (albeit mostly early-stage) pipelines in biotech , and despite our FVE increase, we think its shares are fully valued at recent prices. The R&D day provided few surprises

  9. Roche biotech unit submits skin cancer drug application to US regulator

    Headlines

    Mon, 15 Dec 2014

    ZURICH, Dec 15 (Reuters) - Genentech, U.S. biotech unit of Swiss drugmaker Roche holding, said on Monday it had filed a marketing application to U.S. regulators for the use of

  10. Roche says head of Genentech research unit to retire

    Headlines

    Fri, 12 Dec 2014

    ZURICH (Reuters) - Roche said the head of research operations at its subsidiary Genentech would retire at the end of the year, the latest in a string of executives to leave the Californian biotech unit.

« Prev12345Next »
Content Partners